ABSTRACT Layer-by-layer (LbL)-engineered particles have recently emerged as a promising class of materials for application in biomedicine, with studies progressing from in vitro to in vivo. The versatility of LbL assembly coupled with particle templating has led to engineered particles with specific properties (e.g., stimuli-responsive, high cargo encapsulation efficiency, targeting), thus offering new opportunities in targeted and triggered therapeutic release. This perspective highlights an important development by Poon et al. on tumor targeting in vivo using LbL-engineered nanoparticles containing a pH-responsive poly(ethylene glycol) (PEG) surface layer. Further, we summarize recent progress in the application of LbL particles in the fields of drug, gene and vaccine delivery, and cancer imaging. Finally, we explore future directions in this field, focusing on the biological processing of LbL-assembled particles.
particle template, however, allows the generation of capsules upon selective removal of the core particles. Recent significant advances in the development of LbL particles have enabled efficient cargo encapsulation, triggered release, and antibody-mediated targeting. 9 In addition, LbL capsules have recently been combined with liposomes to form multicomponent, triggerable delivery and microreactor systems. 10 Collectively, these results exemplify the versatility of LbL-engineered particles for integration with diverse polymeric systems, offering significant potential for multistaged controlled release.
In this issue of ACS Nano, Poon et al., report the generation and use of LbL-engineered, pHresponsive nanoparticles for systemic targeting of hypoxic tumors in vivo, highlighting the potential of the multilayered nanoparticles for targeted cancer therapy ( Figure 1 ). 11 Carboxylated quantum dots (QD) were sequentially coated with iminobiotin-functionalized poly(L-lysine) (PLLib), neutravidin (nav), and biotin-functionalized poly(ethylene glycol) (PEG), resulting in pH-responsive QD/PLLib/nav/PEG nanoparticles. In addition to increasing the circulation time, the PEG layer is selectively eroded by the acidity in the hypoxic tumor microenvironment. Consequently, exposure of positively charged layers beneath the PEG layer leads to enhanced tumor retention of the nanoparticles.
These results underscore the importance of the surface properties of LbL particles on exploiting the native environment in biological systems to achieve desirable cellular responses.
In this Perspective, we highlight recent progress made in developing and using LbL-engineered particles for therapeutic delivery, focusing on three keys aspects: (i) engineering LbL particles to interact with specific classes of cells; (ii) cellular processing of LbL particles and drug, gene, and vaccine delivery to cells and animal models; and (iii) key challenges associated with further development of LbL particles to achieve significant outcomes in biomedicine.
Controlling specific interactions between LbL-engineered particles and only targeted cells is of paramount importance for targeted therapies, and represents an immense challenge. Recent studies in this area have demonstrated that LbL particles of sizes ranging from ~20 nm up to several micrometers (in diameter) are readily internalized by diverse types of cells, including epithelial cells, 12, 13 monocytes, 8, 14 and dendritic cells (DCs), 15 17 It was shown that the cellular uptake of PMA SH capsules in human prostate cancer cells resulted in a concomitant decrease in the expression of anti-apoptotic proteins (e.g., survivin) and the activation of autophagy (a process for degrading cellular compartments). Given the close relationship between lysosomes and 5 autophagosomes, the inherent endocytic network will have a significant impact on the internalization, transportation, degradation, and cargo release of LbL-assembled capsules; hence, further studies are required to elucidate the factors that govern cellular uptake and trafficking of LbL-engineered particles.
Delivering drugs encapsulated within LbL particles has significant potential for improving the bioavailability of a range of therapeutics, including chemotherapeutic compounds and short interfering RNA (siRNA) (Scheme 1). A number of LbL particles have been developed for the delivery of therapeutics, including doxorubicin (DOX) and siRNA. 8, 12, [18] [19] [20] Recently, Ochs et al. reported biodegradable, click LbL capsules based on poly(L-glutamic acid) (PGA) that provide a high level of control over drug loading and release. 18 In that study, it was shown that DOX-loaded PGA capsules are internalized by human colorectal cancer cells and following endocytosis, DOX was effectively released from the capsules and further translocated to the nucleus. These drug-loaded capsules resulted in a significant decrease in cell viability. By exploiting the versatility of LbL assembly, these particles can be engineered to incorporate a range of polymer-drug conjugates for targeted applications. The entry of particles via endocytosis can also be used to overcome multidrug resistance in cancer cells, which often limits the effectiveness of chemotherapeutics. This was demonstrated for drugs encapsulated in LbLassembled PGA capsules delivered via endocytic routes, which bypass multidrug resistant efflux pumps (e.g., P-glycoprotein) located on the cell membrane surface, leading to sensitization in resistant cancer cells. 19 As an additional requirement for bioavailability, particle-based delivery systems should also direct and release therapeutics to appropriate intracellular sites of action for optimum activity. The aforementioned lysosomal intracellular fate is unsuited for the delivery of, for example, siRNA, which is rapidly degraded in lysosomes. In such cases, endosomal escape of the siRNA and trafficking to the cytoplasm is required. T cells following cellular uptake of the capsules in APCs in vitro. These capsules were also found to effectively stimulate the proliferation of OVA-specific CD4 and CD8 T cells in mice following the applicability of DS/pARG LbL capsules for vaccine delivery in DCs. 15 Following endo-lysosomal uptake, the capsule wall was ruptured, probably due to the enzymatic degradation by lysosomal proteases, and both the endoplasmatic reticulum (ER) and mitochondria appeared to indirectly interact with the ruptured capsules. Using OVA as a model antigen, it was demonstrated that OVA is processed by proteases into peptides, which resulted in both MHC Class I and II presentation to CD8 and CD4 T cells, respectively. Rivera-Gil et al. further examined enzymatic degradation of DQ-OVA delivered by DS/pARG LbL capsules in mouse fibroblasts, suggesting that the intracellular processing can be controlled by using different degradable polymers. 22 More recently, DS/pARG capsules were explored as antigen delivery vectors for pulmonary immunization. 23 It was shown that these capsules were taken up by APCs cells after pulmonary vaccination, and activated the adaptive (T-cell) immune responses.
In addition to biological processing at the cellular level, effective systemic delivery also requires selective tissue distribution and improved pharmacokinetic properties. This is important for developing nanotechnology-based therapeutics, and the Food and Drug Administration (FDA) and the Alliance for NanoHealth (ANH) have listed the biodistribution of nanoparticles as a top priority. 24 The circulation These results are promising and suggest that LbL particles can be further engineered to improve pharmacokinetics, tumor accumulation, and tumor penetration.
Outlook and Future Challenges
Although early successes in generating and developing LbL-engineered particles for biomedical applications are promising, they also point to important future challenges. Understanding the dynamic interactions between LbL particles and biological systems is fundamental for developing safe and 
